Anavex Life Sciences Corp. · NASDAQ:AVXL

Anavex Life Sciences — Investor Presentation (2016)

38 slides from Anavex Life Sciences's investor presentation, Mar 27, 2016

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    NASDAQ: AVXL Corporate Presenta5on Christopher U. Missling, PhD President & CEO 2016

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presenta,on contains forward-­‐looking statements made within the meaning of the Private Securi,es Li,ga,on Reform Act of 1995 by Anavex™ Life Sciences Corp. and its representa,ves. These statements can be iden,fied by introductory words such as ``expects,'' ``plans,'' ``intends,'' `

  3. Slide 3: Anavex Mission

    Slide 3: Anavex Mission

    Anavex™ Mission Developing Differen,ated Therapeu,cs for the Treatment of Neurodegenera,ve Diseases 3

  4. Slide 4: Anavex Value Proposition

    Slide 4: Anavex Value Proposition

    Anavex™ Value Proposi5on § Lead drug candidates ANAVEX™ 2-­‐73 and ANAVEX™ PLUS Ø Currently in a Phase 2a clinical trial for Alzheimer‘s disease (AD) • ANAVEX 2-­‐73 is an orally available small molecule with posi,ve dose-­‐response curve • Poten,al for preven,ng, disease modifying reversal of mem

  5. Slide 5: Broad Pipeline for Neurodegenerative Diseases

    Slide 5: Broad Pipeline for Neurodegenerative Diseases

    Broad Pipeline for Neurodegenera5ve Diseases ANAVEX™ 2-73 PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALZHEIMER’S ALZHEIMER’S ANAVEX™ PLUS COGNITION IN NEUROPSYCHIATRIC D. EPILEPSY PARKINSON’S RARE DISEASES ANAVEX™ 3-71 (AF710B) ALZHEIMER’S PARKINSON’S ANAVEX™ 1-41 DEPRESSION STROKE PARKINSON’S ALZHEIMER’S

  6. Slide 6: Broad Pipeline for Neurodegenerative Diseases

    Slide 6: Broad Pipeline for Neurodegenerative Diseases

    Broad Pipeline for Neurodegenera5ve Diseases ANAVEX™ 2-73 PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALZHEIMER’S ALZHEIMER’S ANAVEX™ PLUS COGNITION IN NEUROPSYCHIATRIC D. EPILEPSY PARKINSON’S RARE DISEASES ANAVEX™ 3-71 (AF710B) ALZHEIMER’S PARKINSON’S ANAVEX™ 1-41 DEPRESSION STROKE PARKINSON’S ALZHEIMER’S

  7. Slide 7: Sigma-1 Receptor is an Upstream Key Cellular Modulator

    Slide 7: Sigma-1 Receptor is an Upstream Key Cellular Modulator

    Sigma-­‐1 Receptor is an Upstream Key Cellular Modulator ANAVEX2-73 § Blocking NOS § Enabling neuroprotec,on § Reducing protein misfolding § Modula,ng Ca2+ § Reducing oxida,ve stress § Reducing mitochondrial dysfunc,on § Reducing inflamma,on Cauli et al., Neuroscience, Volume 190, 2011, Pages

  8. Slide 8: Recent 3rd Party Publications on Sigma-1R

    Slide 8: Recent 3rd Party Publications on Sigma-1R

    Recent 3rd Party Publica5ons on Sigma-­‐1R: Targe5ng Neurodegenera5ve Indica5ons § Calcium target over-­‐expression IP3 may be involved in causing Alzheimer’s disease, same target regulated through Sigma-­‐1 receptor − K. FoskeN, K. et al., The Journal of Neuroscience, 14 May 2014, 34(20):6910-­‐69

  9. Slide 9: ANAVEX 2-73 Potential Platform Drug for CNS: Pre-Clinical Epilepsy Data

    Slide 9: ANAVEX 2-73 Potential Platform Drug for CNS: Pre-Clinical Epilepsy Data

    ANAVEX™ 2-­‐73 Poten5al PlaWorm Drug for CNS Indica5ons: Pre-­‐Clinical Epilepsy Data Significant An,-­‐Convulsive Ac,on of ANAVEX2-­‐73 Long-­‐Las,ng Effect Shown in PTZ-­‐ Against both MES and PTZ-­‐Induced Convulsions Induced Convulsions *** *** *** *** 100 *** *** 100 90 90 80 MES-­‐induced 80 70

  10. Slide 10: Anti-Depressant and Anti-Anxiety Effect of ANAVEX 2-73

    Slide 10: Anti-Depressant and Anti-Anxiety Effect of ANAVEX 2-73

    An5-­‐Depressant and An5-­‐Anxiety Effect of ANAVEX™ 2-­‐73 in Porsolt Swim Test (PST) and in Open Field Test No observed “seda5ve” effect of ANAVEX 2-­‐73 § Effect of ANAVEX2-­‐73 on immobility ,me on § Effect of ANAVEX2-­‐73 on the number of PST. P<0.01, *p<0.05 and **p<0.01 for 50 and crosses (mo,l

  11. Slide 11: Potential Cognitive Effect of S1R in Neuropsychiatric Diseases

    Slide 11: Potential Cognitive Effect of S1R in Neuropsychiatric Diseases

    Poten5al Cogni5ve Effect of S1R in Neuropsychiatric Diseases ANAVEX2-73 * * Cogni,ve impairment is shown in a number of neuropsychiatric diseases including schizophrenia, major depressive disorder (MDD), au,sm spectrum disorder (ASD), obsessive compulsive disorder (OCD), aNen,on deficit hyperac,vity d

  12. Slide 12: Alzheimer's Market Overview

    Slide 12: Alzheimer's Market Overview

    Alzheimer’s Market Overview Changes in Number of Deaths (All Ages) Between 2000 and 2010 Aging strongest predictor § 40 million Americans are over the age of 65 § 80 million Americans over 65 by 2040 Diagnosis accelera5ng §5 million+ Americans currently diagnosed 12 Sources: Alzheimer’s AssociaJo

  13. Slide 13: Alzheimer's Disease Represents a Large and Fast Growing Healthcare Burden

    Slide 13: Alzheimer's Disease Represents a Large and Fast Growing Healthcare Burden

    Alzheimer’s Disease Represents a Large and Fast Growing Healthcare Burden § $307 billion spent caring for AD pa,ents -­‐ expected to reach $1.5 trillion by 2050 § FDA has approved 4 drugs for AD that only temporarily slow worsening of symptoms for 6-­‐12 months in ~50% of pa,ents § More effec,ve a

  14. Slide 14: Alzheimer's: Complicated Cause with Tragic Outcome

    Slide 14: Alzheimer's: Complicated Cause with Tragic Outcome

    Alzheimer‘s: Complicated Cause with Tragic Outcome ... Stages of Increased Alzheimer’s burden Loss of speech; locomo,on, Terminal consciousness; death Very Severe Full-­‐,me care needed; ins,tu,onalized Can no longer care for self; incon,nent, depressed Severe Can no longer manage personal affairs; a

  15. Slide 15: Alzheimer's Disease is Complicated

    Slide 15: Alzheimer's Disease is Complicated

    Alzheimer‘s Disease is Complicated ... § Removing amyloid beta (A-­‐beta) plaques in the brain might be too simplis5c to be completely effec5ve -­‐ Recent disappointments of bapineuzumab (Pfizer), solanezumab (Eli Lilly), crenezumab (Roche) and gantenerumab (Roche) § More likely: Free-­‐floa5ng par5c

  16. Slide 16: Sigma-1 R: 2nd Line of Defense Against Chronic Stress

    Slide 16: Sigma-1 R: 2nd Line of Defense Against Chronic Stress

    Sigma-­‐1 R: “2nd Line of Defense” Against Chronic Stress Monomer Chronically Distressed Cell: Healthy Cell: Misfolded Proteins Quick Removal Sigma-­‐1R Acer U5liza5on Helping / S5mula5ng Ca2+ dysfunc,on ANAVEX 2-73 Own Body to Aß plays Regain important role in hippocampal Func5onality – memory Mito

  17. Slide 17: ANAVEX 2-73 Reverses Cell Stress and Protein Misfolding

    Slide 17: ANAVEX 2-73 Reverses Cell Stress and Protein Misfolding

    ANAVEX™ 2-­‐73 Reverses Cell Stress and Protein Misfolding Therapeu5c’s Poten5al Mode of Ac5on -­‐ mixed muscarinic / Sig-­‐1R agonist Ca2+ modula,on, reducing inflamma,on, mitochondrial dysfunc,on, and oxida,ve stress, while also reducing both A-­‐beta and Tau ANAVEX 2-73 ANAVEX 2-73 ANAVEX 2-73 Exp

  18. Slide 18: ANAVEX 3-71 Significantly Decreases Hallmark Pathologies in 3xTg-AD Model

    Slide 18: ANAVEX 3-71 Significantly Decreases Hallmark Pathologies in 3xTg-AD Model

    ANAVEX™ 3-­‐71 Significantly Decreases Hallmark Pathologies in 3xTg-­‐Alzheimer’s Disease Model § 10 month-­‐old 3xTg-­‐AD and WT mice § administered p.o. (oral) with tap water or ANAVEX 3-­‐71 (10 mcg/kg/ day) for 2 months 18 Source: Fisher et al., NeurodegeneraJve Diseases 2015 DOI: 10.1159/00044

  19. Slide 19: ANAVEX 2-73 Significantly Improves Memory in Tg2576 Model

    Slide 19: ANAVEX 2-73 Significantly Improves Memory in Tg2576 Model

    ANAVEX™ 2-­‐73 Significantly Improves Memory in Transgenic Alzheimer's Disease Model (Tg2576) P<0.01 § 10 month-­‐old Tg2576 and WT male mice administered p.o. (oral) with tap water or ANAVEX™ 2-­‐73 (3 mg/kg/day); A~er 2 months, tested for place learning in the water-­‐maze; N = 6-­‐12 per group 19

  20. Slide 20: FDA Guidelines for Adaptive Trial and Population PK Design

    Slide 20: FDA Guidelines for Adaptive Trial and Population PK Design

    FDA Guidelines for Adap5ve Trial and Popula5on PK Design ü Fewer pa,ents needed ü Shorter dura,on required ü More likely to demonstrate an effect of the drug (if one exists) ü More informa,ve on the treatment’s effects ü Broader and beNer dose-­‐response informa,on and subgroup effects Leads to mo

  21. Slide 21: ANAVEX 2-73 Efficient Clinical Trial Execution Plan

    Slide 21: ANAVEX 2-73 Efficient Clinical Trial Execution Plan

    ANAVEX™ 2-­‐73 Efficient Clinical Trial Execu5on Plan ANAVEX™2-­‐73-­‐001 Study: • Phase 1 (oral) • Single Ascending Dose (SAD) Completed • Healthy subjects ANAVEX™2-­‐73-­‐002 Study: • Phase 2a (oral) Preliminary Posi5ve Data • Mild-­‐to-­‐moderate AD pa,ents July AAIC 2015 • Adap,ve trial with Popul

  22. Slide 22: ANAVEX 2-73: Phase 2a with Adaptive Trial Design

    Slide 22: ANAVEX 2-73: Phase 2a with Adaptive Trial Design

    ANAVEX 2-­‐73: Phase 2a with Adap5ve Trial Design ANAVEX 2-­‐73 star,ng dose 30mg/50mg (oral) or 3mg, 5mg (IV) Mild-­‐Mod AD ANAVEX 2-­‐73 star,ng dose 30mg/50mg (oral) or pa5ents 3mg, 5mg (IV) + Donepezil Healthy control, Donepezil/ AchEI# No. of Pts: § 32 mild-­‐moderate AD pa,ents (MMSE 16-­‐28)

  23. Slide 23: Part A Cross-Over Design and Part B 52-Week Extension

    Slide 23: Part A Cross-Over Design and Part B 52-Week Extension

    PART A: Bioavailability Cross-­‐Over Design and PART B: 52-­‐Week Open-­‐Label Voluntary Extension ORAL ORAL ORAL Screening Randomiza,on ORAL IV IV IV wash out 12d 12d 12d 5 week 26 week 52 week 1st Period 2nd Period 12 week 38 week [,me] Part A Completed Ongoing Part B PK - Study Extension § Once

  24. Slide 24: ANAVEX 2-73 Safety from Phase 2a

    Slide 24: ANAVEX 2-73 Safety from Phase 2a

    ANAVEX™ 2-­‐73 Safety from Phase 2a § Safety profile § The most common AE was dizziness followed by headache § Events were mild or moderate and reversible with 80% being grade 1 § There were no drug related AEs Grade 3, 4 and 5 § Most (94.4%) observed within first 8 days § AE profile similar to t

  25. Slide 25: Efficacy Data Measurements

    Slide 25: Efficacy Data Measurements

    Efficacy Data Measurements Cogni5on and Func5on § Exploratory cogni,ve measures (Cogstate baNery); (MMSE) § Func,onal measures (ADCS-­‐ADL) Suppor5ve Biomarker Measurements § ERP (P300): fundamental measures of synap,c network performance § ERP target detec,on task measures: direct measure of aNen

  26. Slide 26: ANAVEX 2-73 Significantly Improves Components of Cogstate Tasks at Week 5

    Slide 26: ANAVEX 2-73 Significantly Improves Components of Cogstate Tasks at Week 5

    ANAVEX 2-­‐73 Significantly Improves Components of Cogstate Tasks at Week 5: Effect sizes for Change from Baseline Cogni,ve Cogni,ve Decline Improvement *p<0.05, **p<0.001 § ANAVEX 2-­‐73 improved 5 of 6 Cogstate Tasks at week 5 § n= 30 at baseline and week 5 with on-­‐off-­‐on ANAVEX 2-­‐73 dosing r

  27. Slide 27: ANAVEX 2-73 Improves Cogstate Tasks Relative to AD Control Group

    Slide 27: ANAVEX 2-73 Improves Cogstate Tasks Relative to AD Control Group

    ANAVEX 2-­‐73 Significantly Improves Components of Cogstate Tasks at week 5: Data Rela5ve to Change in AD Control Group Cogni,ve Cogni,ve Decline Improvement Detec,on 0.33 * Meta-­‐analyses indicate Iden,fica,on* high dose of 0.40* donepezil ~0.28 in similar One Back** 0.86** pa,ents# Visual Learning

  28. Slide 28: ANAVEX 2-73 Increases MMSE by +1.5 Points at Week 5

    Slide 28: ANAVEX 2-73 Increases MMSE by +1.5 Points at Week 5

    ANAVEX 2-­‐73 Increases MMSE by +1.5 Points at Week 5 24 23 22 MMSE score 21 Δ = +1.5 points# 20 19 18 MMSE (BASELINE) MMSE (WEEK 5) § ANAVEX 2-­‐73 improved median MMSE by +1.5 points at week 5 § n= 30 at baseline and week 5 with on-­‐off-­‐on ANAVEX 2-­‐73 dosing regimen without any dose op,miza,

  29. Slide 29: Interim Data: ANAVEX 2-73 Increases ADCS-ADL at Week 12

    Slide 29: Interim Data: ANAVEX 2-73 Increases ADCS-ADL at Week 12

    Interim Data: ANAVEX 2-­‐73 Increases ADCS-­‐ADL by +3.21 Points at Week 12 70.00 68.00 66.00 Δ = +3.21 points# ADCS-ADL score 64.00 62.00 60.00 58.00 ADCS-ADL (Baseline PART B) ADCS-ADL (Week 12) § Interim data: ANAVEX 2-­‐73 improved ADCS-­‐ADL signal in 11 out of 14 (78.6%) pa,ents § # p = not

  30. Slide 30: ANAVEX 2-73 Reverses Cognitive Deficits Measured by ERP at Week 5

    Slide 30: ANAVEX 2-73 Reverses Cognitive Deficits Measured by ERP at Week 5

    ANAVEX 2-­‐73 Reverses Cogni5ve Deficits Measured by Standard ERP Methods at Week 5 P300 Amplitude Task Accuracy False Alarms Reac5on Time (µV) (%) (%) (ms) Baseline 5.99±0.58 83.8±.3.9 3.4±1.0 559.0±24.0 Week 5 7.09±0.72 92.6±2.4 1.0±0.5 492.6±23.8* Healthy Control# 7.36±0.39 94.1±1.1 1.1±0.2 458.6±

  31. Slide 31: Future Development

    Slide 31: Future Development

    Future Development § Phase 2a (PART A) results demonstrate an acceptable safety, bioavailability and tolerability/risk profile to con,nue development § Suppor,ve evidence (Cogstate, MMSE, ERP) indica,ng a cogni,ve benefit associated with ANAVEX 2-­‐73 already at 5 week treatment § Guidance received

  32. Slide 32: CNS Landscape

    Slide 32: CNS Landscape

    CNS Landscape Ra5onale Development Phase 5-­‐HT6 antagonist plus Axovant (AXON) donepezil Phase 3 Avanir (AVNR) Sigma 1 Receptor Marketed Heptares M1 agonist, Alzheimer’s Phase 1b (Private) Phase 1/2 Prothena (PRTA) Protein misfolding Prana (PRAN) Alzheimer's Disease Phase 2 GW Pharma Epilepsy Phase

  33. Slide 33: Financial Summary

    Slide 33: Financial Summary

    Financial Summary Symbol: AVXL Shares Outstanding: 34.6 million 52-­‐Week Stock Price Range: $3.16 -­‐ $14.84 Average Daily Volume: 5,261,330 Cash @ 12/31/2015: $13.8 million Cash Burn (est.): ~$600K/month § Well-­‐capitalized to achieve key clinical readouts § No debt 33

  34. Slide 34: Experienced Management Team with Strong Track Record in the CNS Space

    Slide 34: Experienced Management Team with Strong Track Record in the CNS Space

    Experienced Management Team with Strong Track Record in the CNS Space Management and Directors Christopher U. Missling, PhD, MBA Tasos Zografidis, PhD Uli Elben, PhD Kris,na Capiak Bernd Metzner, PhD Elliot Favus, MD Steffen Thomas, PhD Tom Skarpelos Scien5fic Advisory Board Abraham Fisher, PhD Jeffrey

  35. Slide 35: Key Achievements to date and Expected Catalysts in 2016

    Slide 35: Key Achievements to date and Expected Catalysts in 2016

    Key Achievements to date and Expected Catalysts in 2016 þ First pa,ent dosed in Phase 2a study in 2015 Safety and exploratory efficacy þ Phase 2a – Report preliminary data in July AAIC 2015 þ Advance preclinical research with ANAVEX™ 2-­‐73 for Parkinson’s – Grant from Michael J Fox Founda,on (MJFF

  36. Slide 36: Anavex Value Proposition

    Slide 36: Anavex Value Proposition

    Anavex™ Value Proposi5on § Lead drug candidates ANAVEX™ 2-­‐73 and ANAVEX™ PLUS Ø Currently in a Phase 2a clinical trial for Alzheimer‘s disease (AD) • ANAVEX 2-­‐73 is an orally available small molecule with posi,ve dose-­‐response curve • Poten,al for preven,ng, disease modifying reversal of mem

  37. Slide 37: Today every 67 seconds someone develops Alzheimer's

    Slide 37: Today every 67 seconds someone develops Alzheimer's

    “… Today every 67 seconds someone develops Alzheimer’s” ̶ The Alzheimer’s AssociaJon Anavex™ is working on a poten,al solu,on for neurodegenera,ve diseases. 37

  38. Slide 38: Contact Us

    Slide 38: Contact Us

    Contact Us Corporate Office: Anavex™ Life Sciences Corp. 51 West 52nd Street, 7th floor New York, NY 10019 (212) 332 4449 Shareholder & Media Rela5ons: Toll-­‐free: 1-­‐866-­‐505-­‐2895 Outside North America: + 1 (416) 489-­‐0092 Email: ir@anavex.com www.anavex.com NASDAQ: AVXL 38 ANAVEX is a trademark

Source: Internet Archive copy of anavex.com

More decks from Anavex Life Sciences Corp.

All 35 Anavex Life Sciences decks